Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Quisette P JanssenJacob L van DamIsabelle G KivitsMarc G BesselinkCasper H J van EijckMarjolein Y V HomsJoost J M E NuyttensHongchao QiHjalmar J van SantvoortAlice C WeiRoeland F de WildeJohanna W WilminkGeertjan van TienhovenBas Groot KoerkampPublished in: Annals of surgical oncology (2021)
In this meta-analysis, radiotherapy following neoadjuvant FOLFIRINOX was associated with an improved R0 resection rate as compared with neoadjuvant FOLFIRINOX alone, but a difference in survival could not be demonstrated. Randomized trials are needed to determine the added value of radiotherapy following neoadjuvant FOLFIRINOX in patients with (B)PRC.